AstraZeneca (AZN) and Ionis (IONS) Sign Deal to Develop and Commercialise Eplontersen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/27/2022
- Wall Street rallies, snaps longest weekly losing streak in decades
- 'Always Bet on Michael': Dell (DELL) Stock Soars After Crushing Estimates, Analysts Say Results are Impressive
- Credit Suisse Says Tesla (TSLA) Stock Offers an Attractive Entry Point, Sees Nearly 60% Upside From Here
- Citi Downgrades US Equities to Neutral on Recession Risk
- Elon Musk Says Recession Could Last 12 to 18 Months, But 'Actually a Good Thing'
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
- Wall Street jumps on retailer outlook hikes, ebbing Fed fears
- Kohl's (KSS) Ticks Lower as Another Bidder Losing Interest
- 'His Personality Suggests Resolution Depends on Him Alone': Jefferies Discusses Elon Musk, Cuts PT on Tesla (TSLA) on Increased Risk Profile
- Pre-Open Stock Movers 05/27: Dell, Ulta Surge on Earnings Beats; Gap Plunges (more...)
- After-Hours Stock Movers 05/26: Ulta, Dell Jump on Earnings; Gap, American Eagle Sink (more...)
- Pre-Open Stock Movers 05/26: Retailers Dollar Tree, Macy's, and Williams-Sonoma Jump on Results; Nutanix, Snowflake, NVIDIA Fall (more...)
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
Additional Analyses of AstraZeneca's (AZN) ENHERTU Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer
December 9, 2021 9:46 AM ESTNew results from the DESTINY-Breast03 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated higher progression-free survival (PFS) and objective response rate (ORR) in prespecified patient subgroups compared to trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. ENHERTU is a HER2 directed... More
AstraZeneca (AZN) Evusheld Authorized for Emergency Use in the US or Pre-Exposure Prophylaxis (Prevention) of COVID-19
December 8, 2021 4:05 PM ESTAstraZeneca's (NASDAQ: AZN) Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.
The Food and Drug Administration (FDA) granted the EUA for Evusheld for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination,... More
AstraZeneca (AZN) Said to Study Listing of New Vaccines Division - Bloomberg
December 3, 2021 12:44 PM ESTAstraZeneca (NASDAQ: AZN) Said to Study Listing of New Vaccines Division - Bloomberg
Said to Discuss Range of Options for Unit... More
